WallStSmart

Abbott Laboratories (ABT)vsEverpure, Inc. (P)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1046% more annual revenue ($45.13B vs $3.94B). ABT leads profitability with a 13.9% profit margin vs 5.8%. ABT appears more attractively valued with a PEG of 1.32. P earns a higher WallStSmart Score of 57/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

P

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 4.5Value: 3.7Quality: 6.0
Piotroski: 3/9Altman Z: 1.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-27.8%)

Margin of Safety

-27.8%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for P.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$154.45B9/10

Large-cap with strong market position

P3 strengths · Avg: 9.0/10
EPS GrowthGrowth
139.7%10/10

Earnings expanding 139.7% YoY

Debt/EquityHealth
0.169/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
20.4%8/10

Revenue surging 20.4% year-over-year

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

P4 concerns · Avg: 3.5/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Price/BookValuation
16.5x4/10

Trading at 16.5x book value

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : P

The strongest argument for P centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : P

The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 109.6x leaves little room for execution misses.

Key Dynamics to Monitor

ABT profiles as a value stock while P is a growth play — different risk/reward profiles.

P carries more volatility with a beta of 1.45 — expect wider price swings.

P is growing revenue faster at 20.4% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

P scores higher overall (57/100 vs 56/100) and 20.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Everpure, Inc.

TECHNOLOGY · COMPUTER HARDWARE · USA

Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.

Want to dig deeper into these stocks?